Canaloplasty with iTrack™ Advance: Early Intervention to Reduce Glaucoma Medication Burden скачать в хорошем качестве

Canaloplasty with iTrack™ Advance: Early Intervention to Reduce Glaucoma Medication Burden

Why watch drop burden increase when you can get in early with canaloplasty? Interventional glaucoma and canaloplasty with iTrack™ Advance is modern ophthalmology’s answer to traditional drop-based glaucoma management regimes, and in this video, Prof. Norber Koerber (Germany) digs further into why. Watch as he discusses why early intervention matters for patients and physicians, and reviews the research on the compelling numbers behind medication reduction and IOP maintenance with canaloplasty and iTrack™ Advance. The iTrack™ Advance has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma. Indications for Use, USA: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.* The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The ab interno surgical technique is not a cleared indication for the iTrack™ Advance in the USA. The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma. Indications for Use, International: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. For more information in relation to approved labelling and indications for use, please visit https://itrack-advance.com/